IPO News: US Insurtech Lemonade Raises $319M U.S. Stock Market Debut

Insurance provider Lemonade IPO (NYSE:LMND) raised $319 million became 2020's best IPO debut after the mobile-based insurance startup's stock closed up 139%


US insurtech startup Lemonade Inc filed for an initial public offering (IPO) and yesterday evening it made its debut on the New York Stock Exchange (NYSE). It raised US$319 million in its US initial public offering (IPO).

Lemonade priced 11 million shares at US$29 per share, the company said in a statement. The indicated price range earlier on Wednesday was raised to between US$26 and US$28 per share. Lemonade had previously guided for the offering to be priced between US$23 and US$26 per share.

NYSE lemonade ipo stock price

Lemonade’s LMND, +139.34% became 2020’s best IPO debut after the mobile-based insurance startup’s stock closed up 139% to finish at $69.41 on the New York Stock Exchange, hitting an intraday high of $70.80

Lemonade is the latest company to capitalise on the sharp recovery in US investor appetite for new stocks following the coronavirus outbreak.

On Tuesday, US business analytics firm Dun & Bradstreet Holdings Inc raised US$1.7 billion in its IPO after it sold more stock than expected and at a price above its indicated range.

The IPO values Lemonade at US$1.6 billion, SoftBank valued the fintech at around $2.1bn, current estimates put the fintech at around $3.4bn in a funding round led by Japan’s SoftBank and which included insurer Allianz SE and Alphabet Inc’s venture capital arm GV.

Once IPO closes, SoftBank is expected to own a 21.8% stake in the company, with Sequoia Capital and Aleph LP each holding a 8.3% stake, and General Catalyst Group with a 5.9% stake. Among the company’s founders, Daniel Schreiber will hold a 28.3% stake and Shai Wininger will hold a 29% stake.

Goldman Sachs, Morgan Stanley, Allen & Co and Barclays are the managing bookrunners for the offering. The company was set to list its shares on the New York Stock Exchange under the symbol “LMND”


Please enter your comment!
Please enter your name here